Israeli pharmaceutical giant Teva has agreed to establish a joint venture with South Korean pharmaceutical company Handok. Teva will have a 51 percent stake in the venture, and will be in charge of manufacturing and supplying medicine. Handok will market, sell and distribute the products. The South Korean pharmaceutical market is estimated to be worth $14 billion.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments